BPC-157
Targeted Peptide Therapy // IVUSE+

BPC-157

BPC-157. A fifteen-amino-acid peptide derived from human gastric juice that survives enzymatic destruction and activates four parallel repair pathways. The repair signal, delivered directly.

10MG/ML
Tendon & Ligament Repair Angiogenesis & Vascular Support GI Mucosal Protection Anti-Inflammatory & Cytoprotective
Protocol Options

Clinician-prescribed. Ships from a licensed U.S. pharmacy.

The Mechanism

The Repair Signal That Survives Everything.

Most peptides are destroyed within minutes by proteolytic enzymes. BPC-157 survives human gastric juice for over 24 hours. It evolved in the most proteolytically hostile environment in the body and emerged stable enough to function as a persistent repair signal in any tissue it reaches. Four pathways operate in parallel. VEGFR2 activation builds new blood vessels at injury sites by sensitizing endothelium to existing growth factors. Dual nitric oxide modulation (Akt-eNOS and Src-Caveolin-1-eNOS) drives vasodilation and endothelial stability. FAK-paxillin phosphorylation mobilizes fibroblasts to the damage site. GHR upregulation sensitizes connective tissue to circulating growth hormone. One peptide coordinating angiogenesis, cell migration, receptor sensitization, and survival signaling simultaneously.

Clinical Data

The Evidence

24hrs+
Stable in human gastric juice, the harshest proteolytic environment
4
Parallel signaling pathways activated simultaneously for tissue repair
50%
Reduction in eNOS/Caveolin-1 inhibitory binding, doubling available nitric oxide synthase
Huang et al., Scientific Reports, 2020
Comparison

Conventional Tissue Repair Approaches vs. BPC-157

Conventional Tissue Repair ApproachesBPC-157
PRP provides a one-time growth factor bolus without addressing receptor sensitivity VEGFR2 sensitization builds sustained vascular infrastructure at injury sites
Corticosteroid injections reduce inflammation but impair structural healing Drives fibroblast activation and collagen formation, not just inflammation control
NSAIDs suppress prostaglandins needed for early-phase repair Opposes NSAID-induced gastric damage while promoting tissue repair simultaneously
Physical therapy cannot overcome biological supply bottlenecks alone Provides the biological resources (blood supply, cell migration) that rehab needs
Prolotherapy creates controlled irritation without growth factor support Four parallel pathways produce coordinated repair, not isolated interventions
Each approach addresses one dimension of repair in isolation Stable in gastric juice 24hrs+, no carrier or encapsulation required
Product Information

Details

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide first isolated from a protective protein in human gastric juice. Its fifteen-amino-acid sequence shows no homology with any other known peptide. The defining property is stability: it survives human gastric juice for over 24 hours, requiring no carrier or encapsulation. BPC-157 operates through four converging pathways: VEGFR2-mediated angiogenesis, dual-pathway nitric oxide modulation, FAK-paxillin-driven fibroblast migration, and growth hormone receptor upregulation in connective tissue. These pathways run in parallel, producing coordinated repair rather than isolated improvements. A 2025 systematic review of 36 studies confirmed BPC-157's potential to reduce inflammation, promote vascularity, and improve recovery across fracture, muscle, tendon, and ligament injury models. No lethal or toxic dose has been identified across three decades of preclinical research.
Tendon and ligament repair is the most extensively documented benefit. In Achilles tendon transection models, BPC-157 improved every measured parameter: load to failure, functional index, collagen formation, and defect size reduction. The peptide also builds vascular infrastructure at injury sites through VEGFR2 sensitization. GI mucosal protection is the original context of discovery. BPC-157 opposes NSAID-induced gastric damage while promoting tissue repair simultaneously. It is effective both prophylactically and therapeutically, a dual capability standard cytoprotective agents cannot match.
Administer via subcutaneous injection using a 27-31 gauge insulin syringe. Inject into the abdomen, upper arm, or thigh. For musculoskeletal injuries, injection near the site of injury may be preferred. Your prescribing provider will determine dosing frequency and cycle length. Store refrigerated at 36 to 46 degrees Fahrenheit. Protect from light.
BPC-157 has a favorable safety profile across over 100 preclinical studies. No lethal or toxic dose has been identified. A 2025 human pilot study of IV BPC-157 at doses up to 20mg produced no adverse effects. Common injection-related effects include mild site soreness and occasional nausea during initial dosing. Individuals with active malignancy should consult their oncologist due to BPC-157's pro-angiogenic properties.
Disclaimer and Transparency

Important Information About Compounded Injectables

  • Compounded medications are not reviewed or approved by the FDA and do not undergo the same pre-market evaluation as FDA-approved drugs.
  • IVUSE peptide injections are prepared using peptide ingredients by FDA-registered, U.S.-licensed 503A & 503B compounding pharmacies, where available and clinically appropriate.
  • Availability and formulation may vary based on state regulations, evolving clinical guidance, and pharmacy partners.

All prescriptions, treatment decisions, and care plans are made independently by licensed healthcare providers using their professional judgment. Images and product depictions are for illustration only; actual packaging and supplies may vary.

*If you are interested in a prescription product, IVUSE will coordinate a telehealth visit with a licensed medical provider who will determine whether you are an appropriate candidate based on your health profile and current standards of care. If approved, a prescription will be issued and filled by one of our partner pharmacies. All prescriptions are subject to provider discretion and clinical appropriateness.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. All information provided here is for educational purposes only and does not replace personalized medical advice from a qualified healthcare professional.

Stop the medication and contact your provider if you experience persistent or concerning symptoms. Seek immediate medical care if you develop signs of a severe allergic reaction (such as hives, facial swelling, or difficulty breathing) or any rapidly worsening symptom.

After You Order

What happens next

01

Choose Your Protocol

No consultation fee. No hidden costs. Single vials or a full 12-week cycle.

02

Complete Your Clinical Intake

A board-certified clinician reviews your health history, medications, and goals. Asynchronous. No appointments. No waiting rooms.

03

Your Prescription Ships

Compounded by a licensed U.S. pharmacy. Delivered to your door in 2-4 business days. Cold-shipped when required.

Clinical Recommendation

Stack Your Protocol

TB-500
Peptide Therapy

TB-500

Synergistic healing of soft tissue, ligaments, and tendons. TB-500 drives cellular migration to the injury site while BPC-157 protects and stabilizes the tissue as it rebuilds.

Starting at $102.00
GHK-CU
Peptide Therapy

GHK-CU

Wound healing and skin repair at the cellular level. GHK-CU rebuilds the extracellular matrix at the surface while BPC-157 repairs the deeper tissue beneath it.

Starting at $118.00
MOTS-C
Peptide Therapy

MOTS-C

Metabolic performance and ATP support during recovery. MOTS-C supplies the cellular energy that repair demands while BPC-157 directs it toward tissue regeneration.

Starting at $90.00

BPC-157

BPC-157 $696.00